Some info on Cohen & science..
I was looking around and found a "Federal Bio-Technology Transfer Directory Database" at the "Global Village Publishing" website where I ran a search on "paracelsian." The link to what I came up with is www2.gvp.com{@21}?
I'll include a portion of it here. It's somewhat old, but I THINK it deals with our friend Dr. Cohen, and the ever elusive PN355 AndroVir "method of action" which I THINK was finally written about in Science? Besides the kinase inhibition, it seems to get into more detail, going on about "Syncytia or loosely bound aggregates of HIV-infected cells form when HIV-1 envelope proteins on the surface of HIV-infected T lymphocytes interact with CD4 receptors on other T lymphocytes." What that means, or how it pertains to many of us, or the stock price in particular I do not know. But I thought awhile back some of us here were interested in the "science" behind it all, etc.. I'm sure Rick C or some others could add more to this. Well, that's it. Happy reading. Here's part of what I found: beware, it's awfully scientific:
"FULL RECORD:1691 Reducing Cytopathicity in T-Cells by Lentivirus Appl. No.: 08/125,056; Date: Sept. 21, 1993 Inv.: Cohen, D.I.; Samelson, L.E.; Lane, H.C.; Tani, Y. Herbimycin A and related inhibitors of tyrosine kinases which inhibit syncytia formation and related cytopathic effects in HIV-infected T-cells are useful for treatment of HIV-infection. Syncytia or loosely bound aggregates of HIV-infected cells form when HIV-1 envelope proteins on the surface of HIV-infected T lymphocytes interact with CD4 receptors on other T lymphocytes. Formation of syncytia leads to further cell-to-cell transmission of HIV-infection and cell death. Herbimycin A appears to interfere with the interaction of HIV envelope proteins with cellular CD4 receptors. A novel recombinant syncytia-forming T-cell line, HIVenv2-8, which stably expresses HIV gp160, gp120 and gp41 was used for screening and identification of herbimycin and related syncytia inhibitors. Status - Dr. Cohen, et al., reported the in vitro efficacy of herbamycin A and other tyrosine kinase inhibitors in the April 24, 1994 issue of Science. Tyrosine kinase inhibitors apparently interfere with intracellular signaling involved in the activation of T-cells and induce apoptosis in HIV-infected cells. Paracelsian, Inc. (Ithaca, NY) is developing PN355, a tyrosine kinase inhibitor, for treatment of HIV-infection. Status 3D Application Agency/Lab: 3D PHS.NIAID NIH Office of Technology Transfer, NIH; phone: 301-496-7735; FAX: 301-402-0220"
That's it. What the hell are "herbamycin" and "syncytia inhibitors"? :) I'm confused - which is not very uncommon. Go PRLN!!!!
-Rob |
